Replies to post #120563 on Biotech Values

[DewDiligence]

ANDS has failed science and they are in business for the wrong reasons. Another short candidate.

I would have listed ANDS as one of my three shorts if its enterprise value were not so tiny.

A distant second [long] IMO would be BMY.

Not a pure enough HCV play to be mentioned in this context, IMO.